Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Microbot Medical Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MBOT
Nasdaq
8731
http://www.microbotmedical.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Microbot Medical Inc
Microbot Medical Shares Status Following Recent Geopolitical Events
- Apr 15th, 2024 12:30 pm
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
- Feb 7th, 2024 3:08 pm
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
- Feb 5th, 2024 12:30 pm
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
- Jan 30th, 2024 12:20 pm
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
- Jan 18th, 2024 12:20 pm
Microbot Medical (MBOT) Announces Positive GLP Study Results
- Jan 3rd, 2024 3:12 pm
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
- Dec 29th, 2023 1:00 pm
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
- Dec 28th, 2023 12:30 pm
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
- Dec 14th, 2023 1:15 pm
3 Stocks at the Forefront of Medical Robotics
- Dec 10th, 2023 7:31 pm
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
- Dec 7th, 2023 1:00 pm
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
- Nov 21st, 2023 2:12 pm
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
- Nov 13th, 2023 1:30 pm
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
- Nov 8th, 2023 2:10 pm
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
- Oct 31st, 2023 12:25 pm
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
- Oct 24th, 2023 12:19 pm
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
- Oct 19th, 2023 12:20 pm
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
- Oct 17th, 2023 1:28 pm
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
- Sep 27th, 2023 12:30 pm
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
- Sep 8th, 2023 2:02 pm
Scroll